BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34253583)

  • 1. First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody.
    Kist de Ruijter L; Hooiveld-Noeken JS; Giesen D; Lub-de Hooge MN; Kok IC; Brouwers AH; Elias SG; Nguyen MTL; Lu H; Gietema JA; Jalving M; de Groot DJA; Vasiljeva O; de Vries EGE
    Clin Cancer Res; 2021 Oct; 27(19):5325-5333. PubMed ID: 34253583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probody Therapeutic Design of
    Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
    Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT Imaging of
    Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
    Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Kok IC; Hooiveld JS; van de Donk PP; Giesen D; van der Veen EL; Lub-de Hooge MN; Brouwers AH; Hiltermann TJN; van der Wekken AJ; Hijmering-Kappelle LBM; Timens W; Elias SG; Hospers GAP; Groen HJM; Uyterlinde W; van der Hiel B; Haanen JB; de Groot DJA; Jalving M; de Vries EGE
    Ann Oncol; 2022 Jan; 33(1):80-88. PubMed ID: 34736925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
    Mulgaonkar A; Elias R; Woolford L; Guan B; Nham K; Kapur P; Christie A; Tcheuyap VT; Singla N; Bowman IA; Stevens C; Hao G; Brugarolas J; Sun X
    Clin Cancer Res; 2022 Nov; 28(22):4907-4916. PubMed ID: 36074149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
    Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
    Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
    Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
    J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical PET imaging with the novel human antibody
    Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by
    Chomet M; Schreurs M; Nguyen M; Howng B; Villanueva R; Krimm M; Vasiljeva O; van Dongen GAMS; Vugts DJ
    Theranostics; 2020; 10(13):5815-5828. PubMed ID: 32483421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Biologic Evaluation of a Novel
    Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
    J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
    Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
    Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
    Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
    Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Moek KL; Waaijer SJH; Kok IC; Suurs FV; Brouwers AH; Menke-van der Houven van Oordt CW; Wind TT; Gietema JA; Schröder CP; Mahesh SVK; Jorritsma-Smit A; Lub-de Hooge MN; Fehrmann RSN; de Groot DJA; de Vries EGE
    Clin Cancer Res; 2019 Jun; 25(12):3517-3527. PubMed ID: 30745297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated radiosynthesis of [
    Wichmann CW; Poniger S; Guo N; Roselt P; Rudd SE; Donnelly PS; Blyth B; Van Zuylekom J; Rigopoulos A; Burvenich IJG; Morandeau L; Mohamed S; Nowak AK; Hegi-Johnson F; MacManus M; Scott AM
    Nucl Med Biol; 2023; 120-121():108351. PubMed ID: 37224789
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    van der Veen EL; Giesen D; Pot-de Jong L; Jorritsma-Smit A; De Vries EGE; Lub-de Hooge MN
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Humans Imaging with
    Pandit-Taskar N; Postow MA; Hellmann MD; Harding JJ; Barker CA; O'Donoghue JA; Ziolkowska M; Ruan S; Lyashchenko SK; Tsai F; Farwell M; Mitchell TC; Korn R; Le W; Lewis JS; Weber WA; Behera D; Wilson I; Gordon M; Wu AM; Wolchok JD
    J Nucl Med; 2020 Apr; 61(4):512-519. PubMed ID: 31586002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.